Sericin protects against diabetes-induced injuries in sciatic nerve and related nerve cells*

Chengjun Song, Zhenjun Yang, Meirong Zhong, Zhihong Chen

Abstract
Sericin from discarded silkworm cocoons of silk reeling has been used in different fields, such as cosmetology, skin care, nutrition, and oncology. The present study established a rat model of type 2 diabetes by consecutive intraperitoneal injections of low-dose (25 mg/kg) streptozotocin. After intragastrical perfusion of sericin for 35 days, blood glucose levels significantly declined, and the expression of neurofilament protein in the sciatic nerve and nerve growth factor in L4–6 spinal ganglion and anterior horn cells significantly increased. However, the expression of neuropeptide Y in spinal ganglion and anterior horn cells significantly decreased in model rats. These findings indicate that sericin protected the sciatic nerve and related nerve cells against injury in a rat type 2 diabetic model by upregulating the expression of neurofilament protein in the sciatic nerve and nerve growth factor in spinal ganglion and anterior horn cells, and downregulating the expression of neuropeptide Y in spinal ganglion and anterior horn cells.

Key Words
neural regeneration; traditional Chinese medicine; peripheral nerve injury; diabetes mellitus; sericin; sciatic nerve; spinal ganglion cells; anterior horn cells; nerve cells; neurofilament protein; nerve growth factor; neuropeptide Y; streptozotocin; photographs-containing paper; neuroregeneration

Research Highlights
Sericin upregulated the expression of neurofilament protein in the sciatic nerve, and nerve growth factor in spinal ganglion and anterior horn cells, but downregulated the expression of neuropeptide Y in spinal ganglion and anterior horn cells of diabetic rats to protect against type-2 diabetes-induced injuries in the sciatic nerve and related nerve cells.

INTRODUCTION
Diabetic peripheral neuropathy is a common chronic complication of diabetes mellitus, and its morbidity gradually increases with a prolonged course of disease[1-2]. Most Chinese diabetic patients control blood glucose levels by taking Western medicine, but liver and kidney impairments occur early, and some diabetics even lose their ability to participate in normal activities of daily living in a short time[3-4]. Thus, drugs with minimal toxicity and adverse effects are needed for diabetic patients. Sericin is a potential drug candidate that meets the above characteristics. Sericin is a kind of water-soluble protein in the silkworm cocoons, but it is mostly discarded during silk reeling. Recently, sericin has been used in such diverse areas as cosmetology, skin care, nutrition, and oncology[5-7]. The silkworm cocoon soaked in water has been used to reduce blood glucose. Previous studies from our group showed that sericin effectively reduced blood...
glucose, improved blood fat metabolic disorders, and prevented blood glucose elevation in diabetes mellitus\(^8\). Sericin can protect pancreatic islet cells against diabetic injury by inhibiting apoptosis of beta islet cells and downregulating neuropeptide Y protein expression in islet cells\(^9-10\). Moreover, sericin can regulate testicular growth hormone/insulin-like growth factor 1 axis disorder, improve spermatogenic function and protect reproductive injuries in diabetic rats by upregulating testicular proliferating cell nuclear antigen and c-fos expression\(^11-13\). As the main component of the neuron cytoskeleton, neurofilament protein mainly distributes in the cell body and processes of neurons, and plays an important role in maintaining the normal morphology and structure of neurons. Nerve growth factor was first found by Montalcini in the 1950s. It binds to neurotrophic tyrosine kinase receptor type 1 and p75 receptors on the nerve ending and retrogrades to the cell body to induce protein synthesis and axon growth, promote sphingomyelin hydrolysis and nerve fiber regeneration, and inhibit neuron apoptosis\(^14-15\). Neuropeptide Y is extensively distributed in mammals, including the nervous, digestive, cardiovascular, respiratory and urinary systems, and is an important modulator of the neuroendocrine system\(^16-17\). The present study focused on the effects of sericin on diabetic peripheral neuropathy by observing the changes of neurofilament protein, nerve growth factor and neuropeptide Y protein expression, which can reflect the function of nerve cells, in the rat model of streptozotocin-induced type 2 diabetes, and investigated the protective effects of sericin on sciatic nerve and related nerve cells in diabetic rats.

**RESULTS**

Quantitative analysis of experimental animals
A total of 36 male Sprague-Dawley were used; 12 were randomly selected as the control group, and were not treated. The remaining 24 rats were intraperitoneally injected with low-dose streptozotocin (25 mg/kg) for 3 consecutive days to establish type 2 diabetic models. All the rats became diabetic. Twelve rats were randomly selected as the diabetic model group, and did not receive any additional treatment. The sericin group comprised the remaining 12 diabetic rats, which were intragastrically perfused with sericin for 35 days. All 36 rats were included in the final analysis.

**Sericin reduced blood glucose levels in diabetic rats**
The glucose oxidase method showed that the fasting blood glucose level was 10.83 ± 2.03 mM in the control group; the fasting blood glucose level significantly increased in the model group (29.45 ± 4.82 mM; \(P < 0.01\)) compared with the control group, but significantly decreased after sericin treatment (13.20 ± 4.09 mM; \(P < 0.01\)) compared with the model group. None of the rats showed adverse effects after sericin treatment throughout the experiments.

**Sericin promoted neurofilament protein expression in the sciatic nerve of diabetic rats**

Immunohistochemistry showed that neurofilament protein positive products, stained as brown yellow particles, were distributed in the neurites of the sciatic nerve (Figure 1).

![Figure 1](image)

(A) High levels of neurofilament protein expression were observed in the sciatic nerve of control rats.

(B) Significantly reduced levels of neurofilament protein expression were observed in the sciatic nerve of model rats.

(C) Levels of neurofilament protein expression were significantly increased following sericin treatment in diabetic rats.
The neurofilament protein expression level was significantly lower in the model group (0.2067 ± 0.0286) compared with the control group (0.2941 ± 0.0286; *P* < 0.01), but significantly increased in the sericin group (0.2688 ± 0.0550; *P* < 0.05) compared with the model group.

**Sericin promoted nerve growth factor expression in L₄₋₆ spinal ganglion and anterior horn cells**

Immunohistochemistry showed nerve growth factor protein positive products in the cytoplasm and nuclei of L₄₋₆ spinal ganglion and anterior horn cells in all groups, presented as brown yellow particles mainly in the cytoplasm (Figures 2, 3).

**Figure 2** Effect of sericin on nerve growth factor expression in spinal ganglion cells of diabetic rats (immunohistochemistry, × 200).

Nerve growth factor positive products were presented as brown yellow particles.

(A) High levels of nerve growth factor expression were observed in spinal ganglion cells of control rats.

(B) Significantly reduced levels of nerve growth factor expression were observed in spinal ganglion cells of model rats.

(C) Levels of nerve growth factor expression in spinal ganglion cells were significantly increased following sericin treatment in diabetic rats.

**Figure 3** Effect of sericin on nerve growth factor expression in anterior horn cells of diabetic rats (immunohistochemistry, × 200).

Nerve growth factor positive products were presented as brown yellow particles.

(A) High levels of nerve growth factor expression were observed in anterior horn cells of control rats.

(B) Significantly reduced levels of nerve growth factor expression were observed in anterior horn cells of model rats.

(C) Levels of nerve growth factor expression in anterior horn cells were significantly increased following sericin treatment in diabetic rats.

Nerve growth factor protein expression in spinal ganglion and anterior horn cells was significantly lower in the model group compared with the control group (*P* < 0.01), and was significantly higher in the sericin group compared with the model group (*P* < 0.01; Table 1).

**Sericin decreased neuropeptide Y expression in L₄₋₆ spinal ganglion and anterior horn cells**

Neuropeptide Y protein positive products distributed in the cytoplasm of L₄₋₆ spinal ganglion and anterior horn cells of all groups, presented as brown yellow particles (Figures 4, 5).
Neuropeptide Y protein expression in spinal ganglion and anterior horn cells was significantly greater in the model group compared with the control group (\( P < 0.01 \); Table 1), and was significantly less in the sericin group compared with model group (\( P < 0.01 \); Table 1).

### Table 1  Nerve growth factor and neuropeptide Y expression in spinal ganglion and anterior horn cells of rats

<table>
<thead>
<tr>
<th>Group</th>
<th>Spinal ganglion cells</th>
<th>Anterior horn cells</th>
<th>Spinal ganglion cells</th>
<th>Anterior horn cells</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nerve growth factor</td>
<td>Neuropeptide Y</td>
<td>Nerve growth factor</td>
<td>Neuropeptide Y</td>
</tr>
<tr>
<td>Control</td>
<td>0.411 ±0.035 3</td>
<td>0.178 ±0.045 3</td>
<td>0.118 ±0.023 8</td>
<td>0.074 ±0.022 1</td>
</tr>
<tr>
<td>Model</td>
<td>0.217 ±0.031 9</td>
<td>0.511 ±0.033 3</td>
<td>0.040 ±0.006 9</td>
<td>0.139 ±0.022 2</td>
</tr>
<tr>
<td>Sericin</td>
<td>0.295 ±0.052 2</td>
<td>0.312 ±0.045 5</td>
<td>0.086 ±0.020 3</td>
<td>0.067 ±0.032 6</td>
</tr>
</tbody>
</table>

Relative expression levels of nerve growth factor and neuropeptide Y were represented by the area ratio of nerve growth factor and neuropeptide Y products to field of view (200 ×). Data are expressed as mean ± SD of 12 rats from each group. The multiple sample comparison was conducted using one-way analysis of variance; intergroup comparisons using the \( q \)-test. \( ^aP < 0.01, \) vs. model group.

Figure 4  Effect of sericin on neuropeptide Y expression in spinal ganglion cells of diabetic rats (immunohistochemistry, × 200).

Neuropeptide Y positive products were presented as brown yellow particles.

(A) Low levels of neuropeptide Y expression were observed in spinal ganglion cells of control rats.

(B) Significantly increased levels of neuropeptide Y expression were observed in spinal ganglion cells of model rats.

(C) Levels of neuropeptide Y expression in spinal ganglion cells of diabetic rats were significantly decreased following sericin treatment.

Figure 5  Effect of sericin on neuropeptide Y expression in anterior horn cells of diabetic rats (immunohistochemistry, × 200).

Neuropeptide Y positive products were presented as brown yellow particles.

(A) Low levels of neuropeptide Y expression were observed in anterior horn cells of control rats.

(B) Significantly increased levels of neuropeptide Y expression were observed in anterior horn cells of model rats.

(C) Levels of neuropeptide Y expression in anterior horn cells of diabetic rats were significantly decreased following sericin treatment.
DISCUSSION

Effects of sericin on neurofilament protein expression in the sciatic nerves of diabetic rats

Neurofilament protein plays a role in axoplasmic transport, and serves as the major marker identifying function of synapses\(^{18}\). In addition, neurofilament protein is associated with DNA transcription and translation\(^{18}\).

Studies showed evident gene alterations in skeletal proteins occur in diabetes mellitus\(^{19-20}\). Neurofilament protein expression is reduced in the nervous system of diabetics, with accompanying decreases in the quantity and density of neurofilament protein-positive fibers and microtubules\(^{21-22}\). The reduced neurofilament protein expression results from a disturbance in neuronal substance synthesis and transport, leading to abnormal activities in the nervous system\(^{23-24}\). In the present study, neurofilament protein expression in the sciatic nerve was significantly elevated in the sericin group compared with the model group, indicating that sericin can increase neurofilament protein expression in the sciatic nerve, improve neuronal axoplasmic transport, and maintain the normal morphology and structures of neurons in diabetes mellitus. The sericin-increased neurofilament protein expression allows neurofilament protein to coordinate molecular information transfer and substance exchange among neurons, recover functions of the sciatic nerve, and protect the sciatic nerve.

Effects of sericin on nerve growth factor expression in the spinal ganglion and anterior horn cells of diabetic rats

Studies showed that nerve growth factor synthesis is reduced in diabetes mellitus because of a lack of insulin and hyperglycemia. In diabetes mellitus models, the affinity of nerve growth factor for the neurotrophic tyrosine kinase receptor type 1 receptor is decreased and nerve growth factor reverse axoplasmic transport is injured, leading to reduced nerve growth factor expression in various tissues\(^{25-26}\). Results from the present study showed that nerve growth factor expression in spinal ganglion and anterior horn cells significantly increased in the sericin group compared with the model group, demonstrating that sericin can protect peripheral nerves against diabetic-induced injury.

Effects of sericin on neuropeptide Y expression in the spinal ganglion and anterior horn cells of diabetic rats

Neuropeptide Y expression is the highest in the mammalian nervous system, specifically in the spinal cord, hippocampus, basal nuclei, hypothalamus and cortex\(^{27}\). In the nervous system, neuropeptide Y can excite synapses and is closely correlated with sympathetic preganglionic neurons, indicating that neuropeptide Y may participate in neuromodulator or neuroendocrine release, and can inhibit neurotransmitter release from various neurons\(^{28-29}\). Neuropeptide Y also resides in the heart and surrounding blood vessels\(^{30-31}\). It constricts blood vessels and vascular smooth muscle, enhances the sensitivity of blood vessels to adrenaline and 5-hydroxytryptamine, and suppresses the dilatation of blood vessels to adenosine and acetylcholine, significantly reducing blood flow to corresponding organs\(^{32-34}\).

In conclusion, neuropeptide Y expression in the spinal ganglion and anterior horn cells was significantly increased in the model group compared with the controls, which may result in nervous system injury because of nerve tissue ischemia and hypoxia induced by reduced neurotransmitter release and vasoconstriction. However, compared with the model group, neuropeptide Y expression significantly declined following sericin treatment, indicating that sericin can reduce neuropeptide Y expression, attenuate the inhibitory effects of neuropeptide Y on neurotransmitter release and vasoconstriction to ameliorate nerve tissue ischemia and hypoxia, restore nerve physiologic function, and protect peripheral nerves against diabetes mellitus-induced injury.

MATERIALS AND METHODS

Design

A randomized, controlled, animal study.

Time and setting

The experiments were performed at the Institute of Basic Medicine, Chengde Medical University, China from June 2010 to September 2011.

Materials

Experimental animals

A total of 36 healthy male Sprague-Dawley rats of clean grade, weighing 200–250 g, were provided by the Experimental Animal Center of Hebei Medical University (license No. 712024). They were housed at 20 ± 2°C with a humidity of 40–70%. Animal procedures were conducted in accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals, formulated
Sericin was made from color silkworm cocoons (Sericultural Research Institute, Chengde Medical University) by soaking, water decoction, filtration and condensation.

**Methods**

**Establishment of type 2 diabetic models**
The rats were intraperitoneally injected with 2% streptozotocin (25 mg/kg; Sigma, St. Louis, MO, USA; dissolved in citric acid-sodium citrate buffer, pH 4.4) for 3 consecutive days to establish type 2 diabetic models. Rats were included if the fasting blood glucose was ≥ 16.7 mM after 7 days[36-37]. The control group rats were normally fed and intraperitoneally injected with the same volume of citric acid-sodium citrate buffer.

**Sericin treatment**
Following model establishment, sericin group rats were intragastrically perfused with sericin (2.4 g/kg per day), once a day for 35 consecutive days[38-39]. The control and model groups were intragastrically perfused with the same volume of normal saline for 35 days.

**Blood glucose detection**
All rats were deprived of food for 12 hours, and the rats were anesthetized by intraperitoneal injection with 4% chloral hydrate. 3 mL of blood was harvested from the posterior orbital venous plexus, centrifuged at 3 000 r/min for 20 minutes, and serum was stored at −20°C. Blood glucose levels were detected using the glucose oxidase method (Blood Glucose Detection Kit, No. 20071030; Baoding Great Wall Clinical Reagents Co., Ltd., Baoding, China) in a Boehringer Mannheim/Hitachi 717 automatic clinical biochemical analyzer (Hitachi, Tokyo, Japan)[8].

**Immunohistochemistry detection for neurofilament protein, nerve growth factor and neuropeptide Y expression**
The rats were sacrificed after the blood sampling, and the sciatic nerve (4 cm above the knee joint), spinal cord at L4-L6 levels and corresponding spinal ganglia were harvested, fixed in Bouin’s solution, paraffin embedded, and sectioned into 5-μm-thick blocks. The expression level of neurofilament protein in sciatic nerve cells, and of nerve growth factor and neuropeptide Y in spinal ganglion and anterior horn cells was determined using streptavidin-peroxidase immunohistochemistry[12,40]. The sections were incubated with mouse anti-neurofilament protein polyclonal antibody (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-nerve growth factor polyclonal antibody (1:50; Santa Cruz Biotechnology) and rabbit anti-neuropeptide Y polyclonal antibody (1:50; Wuhan Boster, Wuhan, China) overnight at 4°C, followed by biotin-labeled goat anti-rabbit/mouse IgG (undiluted; Beijing Zhongshan Goldenbridge Biotechnology, Beijing, China) at 37°C for 30 minutes. The sections were visualized by diaminobenzidine, and the reaction was terminated by tap water. The nuclei were counterstained with hematoxylin. Negative controls were treated with PBS instead of the primary antibody. A positive neurofilament protein reaction was documented by brown yellow particles in the neurites of sciatic nerves; positive reactions of nerve growth factor and neuropeptide Y were represented by brown yellow particles in the nuclei or cytoplasm of spinal ganglion and anterior horn cells. Six rats from each group and six sections from each rat were randomly selected. Three fields of view were randomly selected from each section and quantitatively analyzed by 200 × light microscope (Olympus, Tokyo, Japan) using the MiVnt image analysis system (Echung Electronics, Shandong, China). Relative expression levels were represented by the mean value of the area ratio of positive products to field of view[41].

**Statistical analysis**
Data were analyzed using SPSS version 15.0 (SPSS, Chicago, IL, USA) and were expressed as mean ± SD. Multiple sample comparison was made by one-way analysis of variance, and intergroup differences were compared by q-test.

**Acknowledgments:** We thank the Institute of Basic Medicine, Chengde Medical University for technical support.

**Author contributions:** Chengjun Song conceived and designed the study, conducted data analysis and wrote the manuscript. Zhenjun Yang conducted data analysis. Meirong Zhong fed the experimental animals and contributed to statistical analysis. Zhihong Chen conceived and designed the study, revised the manuscript and guided the study. All authors approved the final version of the paper.

**Conflicts of interest:** None declared.

**Ethical approval:** This study received permission from the Animal Ethics Committee of Hebei Province, China.

**Author statements:** The manuscript is original, has not been submitted to or is not under consideration by another publication, has not been previously published in any language or any form, including electronic, and contains no disclosure of confidential information or authorship/patent application disputes.
REFERENCES


(Edited by Xu F, Wu ZB/Su LL/Song LP)